Evidence map›Paper›PMID 29043374›Full record

ReviewDer Urologe. Ausg. A2017

[Overactive bladder-which treatment when?]

J Pannek

Erratum issuedAbstract readComparative StudyReview
PubMed Publisher
In one paragraph

Review in Der Urologe. Ausg. A, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

J PannekNeuro-Urologie, Schweizer Paraplegiker-Zentrum, Guido A. Zäch-Straße 1, CH - 6207, Nottwil, Schweiz. juergen.pannek@paraplegie.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The term OAB (overactive bladder) describes a symptom complex. Therefore, initial treatment should be based on clinical symptoms and the results of basic diagnostics. Patient preference is essential for the choice of the initial treatment. Behavioural therapy, electrostimulation and medical treatment are available treatment options. If these are not effective, extended diagnostic examinations should be performed prior to minimally invasive treatments, like onabotulinumtoxin injections in the detrusor or sacral neuromodulation. Surgical interventions like augmentation cystoplasty are rarely required today.

Indexed as

Behavior TherapyBotulinum Toxins, Type ADiagnosis, DifferentialElectric Stimulation TherapyFemaleGabapentinHumansInjections, IntramuscularLumbosacral PlexusMaleMuscarinic AntagonistsPatient PreferencePhysical Therapy ModalitiesSolifenacin SuccinateTadalafilUrinary BladderBotulinum Toxins, Type AGabapentinMuscarinic Antagonistsonabotulinum toxin ASolifenacin SuccinateTadalafilElectrostimulationMuscarin receptor antagonistsNocturiaOnabotulinumtoxinSacral neuromodulation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.